Cadrenal Therapeutics, Inc. current report, 19 January 2023

Full document

Cadrenal Therapeutics, Inc. Form 8-K Summary

Business context and reporting period

This Form 8-K, signed January 25, 2023, reports events occurring primarily from January 19 through January 24, 2023, including Cadrenal’s initial public offering, related securities issuances, governance changes, executive employment agreements, and adoption of an equity incentive plan. The company is a biotechnology issuer developing tecarfarin. Its common stock began trading on Nasdaq under the symbol CVKD on January 20, 2023.

Key financial and capital markets information

  • IPO: 1,400,000 common shares were sold at $5.00 per share, generating gross proceeds of $7.0 million. Net proceeds after underwriting discounts, commissions, and offering expenses are not provided in the filing text.
  • Underwriter warrant: Boustead Securities received a five-year warrant to purchase 84,000 shares at $6.00 per share, equal to 120% of the IPO price.
  • Additional equity issued: The company issued 600,000 shares to HESP LLC, issued 1,140,700 shares upon conversion of convertible promissory notes, and issued 250,000 shares upon exercise of outstanding warrants.
  • Executive equity: Following the IPO, the company granted 50,000 common shares to CFO Matthew Szot under the 2022 Successor Equity Incentive Plan.
  • Revenue, profit, cash flow, margins, debt, and liquidity: The filing does not provide current-period financial statements or clear values for these metrics.

Material changes versus the prior comparable period

  • The company completed its IPO and became a Nasdaq-listed public company.
  • Convertible notes were converted into 1,140,700 common shares, and 250,000 shares were issued upon warrant exercise, changing the company’s capital structure.
  • The company issued 600,000 shares to HESP LLC pursuant to an amendment to an asset purchase agreement.
  • Glynn Wilson, John Murphy, and Steven Zelenkofske joined the board as Class I, Class II, and Class III directors, respectively. Board audit, compensation, and nominating/governance committees were established.
  • Matthew Szot and Douglas Losordo entered into employment agreements as CFO and Chief Medical Officer, respectively, succeeding their acting roles.
  • The 2022 Successor Equity Incentive Plan became effective.

Guidance, outlook, risks, contingencies, and unusual items

  • The filing announces fast track designation for tecarfarin but does not provide financial guidance, clinical-development milestones, or a commercialization forecast.
  • Existing officers, directors, and pre-IPO stockholders agreed, subject to exceptions, to lock-up restrictions generally lasting six to twelve months.
  • The executive employment agreements provide severance, equity acceleration, benefits continuation, and change-in-control protections under specified circumstances. CFO base salary is $375,000 with a target bonus of up to 50%; CMO base salary is $425,000 with a target bonus of 40%.
  • The company entered into indemnification agreements with its directors and maintains similar agreements with executive officers.
  • The unregistered issuances relied on Securities Act exemptions under Sections 4(a)(2) and 3(a)(9); certain shares were included in a resale prospectus, creating potential future resale dilution.
  • The filing text does not quantify the company’s post-IPO cash balance, cash runway, operating burn, outstanding debt after conversion, or total shares outstanding.

Important facts for investors to verify

  • Reconcile the $7.0 million gross IPO proceeds with net proceeds and offering expenses.
  • Verify the fully diluted share count, including the IPO shares, HESP shares, note-conversion shares, warrant exercises, representative’s warrant, and executive equity grant.
  • Review the underwriting agreement, representative’s warrant, asset purchase amendment, and employment agreements for detailed obligations and contingencies.
  • Confirm post-IPO cash, liquidity runway, remaining debt, and financing requirements in the next periodic report.
  • Assess the clinical, regulatory, and commercial implications of tecarfarin’s fast track designation; the designation does not establish approval or commercial success.